| |
| |
|
| Insider
Information: |
Khattar Jack A. |
| Relationship: |
Director |
| City: |
Rockville |
| State: |
MD |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
1,370,341 |
|
|
Indirect Shares
|
2,118,700 |
|
|
| Direct
Value |
$27,520,575 |
|
|
|
Indirect Value
|
$30,745,072 |
|
|
| Total
Shares |
3,489,041 |
|
|
| Total
Value |
$58,265,647 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
1
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-1.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -42.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Supernus Pharmaceuticals Inc |
SUPN |
President, CEO, Director |
2024-02-28 |
915,217 |
2024-02-28 |
1,022,450 |
Premium* |
|
|
Tesaro, Inc. |
TSRO |
President, CEO, Director |
2016-03-29 |
444,124 |
2016-03-29 |
1,096,250 |
Premium* |
|
|
Scpharmaceuticals Inc. |
SCPH |
Director |
2021-12-03 |
5,000 |
2021-12-03 |
0 |
Premium* |
|
|
Cognition Therapeutics Inc |
CGTX |
Director |
2023-06-09 |
6,000 |
2023-06-09 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2024-02-28 |
4 |
D |
$27.94 |
$469,057 |
D/D |
(16,788) |
915,217 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2024-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
932,005 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2024-02-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(16,500) |
1,022,450 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2024-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
16,500 |
897,005 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-12-22 |
4 |
D |
$27.66 |
$330,758 |
D/D |
(11,958) |
880,505 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-12-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
892,463 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-09-07 |
4 |
D |
$32.10 |
$539,408 |
D/D |
(16,804) |
867,463 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-09-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
35,000 |
884,267 |
0 |
- |
|
| CGTX |
Cognition Therapeutics In... |
Director |
– • – |
2023-06-09 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
6,000 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-05-11 |
4 |
D |
$36.47 |
$547,232 |
D/D |
(15,005) |
849,267 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-05-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
31,250 |
864,272 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-03-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
833,022 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(8,750) |
1,038,950 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,750 |
813,022 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-03 |
4 |
S |
$42.02 |
$8,404 |
D/D |
(200) |
804,272 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-03 |
4 |
OE |
$9.56 |
$3,155 |
D/D |
330 |
804,472 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-02 |
4 |
AS |
$42.06 |
$569,088 |
D/D |
(13,532) |
804,142 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-02 |
4 |
OE |
$9.56 |
$215,243 |
D/D |
22,515 |
817,674 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-01 |
4 |
AS |
$42.01 |
$12,602 |
D/D |
(300) |
795,159 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-02-01 |
4 |
OE |
$9.56 |
$4,761 |
D/D |
498 |
795,459 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-01-31 |
4 |
AS |
$42.01 |
$41,002 |
D/D |
(976) |
794,961 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-01-31 |
4 |
OE |
$9.56 |
$15,487 |
D/D |
1,620 |
795,937 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-01-18 |
4 |
AS |
$40.40 |
$199,394 |
D/D |
(4,936) |
794,317 |
0 |
% |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-01-18 |
4 |
OE |
$9.56 |
$77,245 |
D/D |
8,080 |
799,253 |
0 |
- |
|
| SUPN |
Supernus Pharmaceuticals ... |
President, CEO |
• • – |
2023-01-17 |
4 |
AS |
$40.03 |
$1,018,728 |
D/D |
(25,446) |
791,173 |
0 |
% |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
